Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
Gain Therapeutics, Inc. (GANX)
Company Research
Source: GlobeNewswire
BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. “The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson’s disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson’s Disease and Movement Disorders and the Michael J Fox Foundation Annual Parkinson's Disease Therapeutics Conference demonstrated target engagement with a 53% increase in GCase activity along with favorable safety and tolerability in healthy volunteers. We believe these outcomes derisk the upcoming Phase 1b study in pat
Show less
Read more
Impact Snapshot
Event Time:
GANX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GANX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GANX alerts
High impacting Gain Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GANX
News
- Gain Therapeutics To Present At Biotech Showcase 2025 [Yahoo! Finance]Yahoo! Finance
- Gain Therapeutics To Present At Biotech Showcase 2025GlobeNewswire
- Gain Therapeutics, Inc. (NASDAQ: GANX) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- Gain Therapeutics, Inc. (NASDAQ: GANX) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $7.00 price target on the stock.MarketBeat
- Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
GANX
Earnings
- 11/14/24 - Beat
GANX
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 10/21/24 - Form 8-K
- GANX's page on the SEC website